Immuneering Announces Updated Clinical Data From Ongoing Phase 2a Trial Evaluating Atebimetinib In Combination With mGnP In First-Line Metastatic Pancreatic Ductal Adenocarcinoma

뉴스 본문을 불러오고 있어요.

Immuneering Announces Updated Clinical Data From Ongoing Phase 2a Trial Evaluating Atebimetinib In Combination With mGnP In First-Line Metastatic Pancreatic Ductal Adenocarcinoma | 웨이프 WAPE

Immuneering Announces Updated Clinical Data From Ongoing Phase 2a Trial Evaluating Atebimetinib In Combination With mGnP In First-Line Metastatic Pancreatic Ductal Adenocarcinoma

기사 요약

관련 종목

댓글 —